KDventures AB Stock

KDV B

SE0002190926

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 20:00:00 23/07/2026 +04			5-day change	1st Jan Change
0.2470 ^SEK	+0.41%		+0.61%	-43.35%

07-09	KD Ventures portfolio company PharmNovo raises SEK 39m	FW
06-25	KDventures: Anacardio's heart failure study published in The Lancet	FW

Analysts' recommendations: KDventures AB

05-11	Redeye: KD Ventures trading at a steep discount to NAV	FW
05-11	Redeye initiates coverage of KD Ventures with a fair value of SEK 1.0 per share	FW
11-17	DNB Carnegie Lowers Target Value for Karolinska Development to SEK 1.4-2.1 per Share	FW
11-04	Karolinska Development's Modus Therapeutics gets approval for 2nd part of phase 2 study	RE
11-04	Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemia	CI

More recommendations

Managers and Directors: KDventures AB

Manager	Title	Age	Since
Viktor Drvota CEO	Chief Executive Officer	61	01/06/2017
Hans Christopher Toll DFI	Director of Finance/CFO	58	01/10/2022
Mikaela Sörman CIO	Chief Investment Officer	-	-

Director	Title	Age	Since
Theresa Y. Y. Tse BRD	Director/Board Member	33	28/11/2017
Anna Lefevre Skjöldebrand BRD	Director/Board Member	57	19/02/2021
Benjamin Toogood CHM	Chairman	50	18/12/2024

More insiders

Other Medical Equipment, Supplies & Distribution

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KDVENTURES AB	+0.41%	+0.61%	-74.85%	-84.85%	16.67M
ABBOTT LABORATORIES	+0.18%	+1.94%	-19.93%	-11.85%	175B
MEDTRONIC PLC	+0.15%	-1.85%	-10.87%	-7.81%	105B
CENCORA, INC.	+1.49%	-0.95%	+3.96%	+58.40%	59.35B
HOYA CORPORATION	-1.15%	-2.54%	+26.45%	+54.85%	50.71B
BECTON, DICKINSON AND COMPANY	-0.12%	-4.35%	-16.22%	-42.24%	42.15B
MEDLINE INC.	+1.21%	-8.47%	-	-	31.82B
DEXCOM, INC.	-1.33%	-9.62%	-18.45%	-46.03%	27.2B
WEST PHARMACEUTICAL SERVICES, INC.	-0.82%	-1.92%	+56.39%	-5.79%	25.11B
STERIS PLC	+0.03%	-4.74%	-6.58%	-9.24%	20.53B
Average	+0.03%	-3.02%	-6.68%	-10.51%	53.73B
Weighted average by Cap.	+0.18%	-1.51%	-5.87%	-0.04%

See all sector performances

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâ€™s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâ€™s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

08-26 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
23/07/26	SEK 0.2470	+0.41%	351,628
22/07/26	SEK 0.2460	+1.23%	277,735
21/07/26	SEK 0.2430	0.00%	604,114
20/07/26	SEK 0.2430	-1.02%	423,137
17/07/26	SEK 0.2455	0.00%	319,335

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Cap	163M 16.67M 14.66M 13.62M 12.52M 23.49M 1.61B 23.91M 63.52M 787M 62.57M 61.22M 2.73B	P/E 2024	-31.7x	P/E 2025	-0.61x
Enterprise Value	140M 14.33M 12.61M 11.71M 10.77M 20.2M 1.39B 20.56M 54.63M 677M 53.81M 52.65M 2.35B	EV / Sales 2024	118x	EV / Sales 2025	56.8x
Free-Float	65.1%	Yield 2024 *	-	Yield 2025	-

07-09	KDventures' : portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	PU
07-09	KDventures’ portfolio company PharmNovo secures capital ahead of phase 2 study; holding written down	AQ
06-30	Change of number of shares and votes in KDventures AB	AQ
06-25	KDventures' : portfolio company AnaCardio's clinical study of drug candidate AC01 published in The Lancet	PU
06-25	KDventures’ portfolio company AnaCardio’s clinical study of drug candidate AC01 published in The Lancet	AQ

1 day	+0.41%
1 week	+0.61%
Current month	+1.65%
1 month	-2.18%
3 months	-14.53%
6 months	-18.08%
Current year	-43.35%

1 week	0.24	0.25
1 month	0.24	0.27
Current year	0.2	0.45
1 year	0.2	1.24
3 years	0.2	1.95
5 years	0.2	11.24
10 years	0.2	11.24

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/03/23	Johan Dighed	Buy	General Counsel	50,000	0.0187%
30/09/22	Johan Dighed	Buy	General Counsel	40,187	0.0150%
08/03/22	Benjamin Toogood	Buy	Chairman	64,001	0.0367%

KDventures AB Stock

Stocks

KDV B

SE0002190926

Medical Equipment, Supplies & Distribution

Valuation: KDventures AB

Chart: KDventures AB

Latest news : KDventures AB

Analysts' recommendations: KDventures AB

Press Releases: KDventures AB

Quotes and Performance

Course Extremes

Managers and Directors: KDventures AB

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

	2024	2025
Net sales	1.84M 188K 165K 154K 141K 265K 18.22M 270K 717K 8.89M 706K 691K 30.83M	1.67M 171K 150K 140K 129K 241K 16.56M 245K 652K 8.08M 642K 628K 28.03M
Net income	-8.1M -829K -729K -677K -623K -1.17M -80.3M -1.19M -3.16M -39.16M -3.11M -3.05M -136M	-194M -19.84M -17.45M -16.21M -14.91M -27.96M -1.92B -28.46M -75.61M -937M -74.49M -72.88M -3.25B
Net Debt	-39.9M -4.08M -3.59M -3.34M -3.07M -5.75M -395M -5.86M -15.56M -193M -15.33M -15M -669M	-22.8M -2.33M -2.05M -1.91M -1.75M -3.29M -226M -3.35M -8.89M -110M -8.76M -8.57M -382M